Related Experiment Video
Updated: Mar 6, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study
Masakatsu Kanazawa1, Hiroyuki Ohba1, Shingo Nishiyama1
1Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan.
Abstract:
The objective of the present PET study was to compare the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on serotonergic neuronal systems and mitochondrial complex I (MC-I) activity with that of dopamine in conscious rhesus monkeys (Macaca mulatta). Methods: A Parkinson disease monkey model was prepared by repeated administration of MPTP. For the PET measurements, normal and MPTP-treated conscious monkeys received an intravenous injection of 11C-DASB for serotonin transporter, 18F-MPPF for serotonin 1A receptor, 11C-PE2I for dopamine transporter, 11C-6MemTyr for dopamine synthesis, 11C-raclopride for dopamine D2 receptor, or 18F-BCPP-EF for MC-I. Serotonin and dopamine parameters were calculated using time-activity curves in the cerebellum as the input function. The total distribution volume of 18F-BCPP-EF was assessed using Logan plot graphical analysis with metabolite-corrected plasma as the input function. Results: MPTP-induced diffuse reductions in MC-I activity were observed throughout the brain, except the cerebellum. Significant reductions in the presynaptic dopamine parameters-dopamine transporter and dopamine synthesis-were detected in the striatum and substantia nigra pars compacta of MPTP-treated monkeys, whereas no significant differences in postsynaptic dopamine D2 receptor binding were observed. Serotonin transporter binding was reduced by MPTP not only in striatal regions but also in extrastriatal regions. In contrast, serotonin 1A receptor binding was unaffected by MPTP anywhere in the brain. In the cortex, the reduction of serotonin transporter binding correlated with that of MC-I. Conclusion: The results obtained by multiparametric PET measurements in a Parkinson disease monkey model demonstrated that chronic MPTP treatment induced reductions not only in the dopaminergic system in the nigrostriatal pathway but also in serotonin transporter in the cortical and subcortical regions. These results suggest that the neurotoxicity of MPTP is not exclusive to the nigrostriatal pathway, as predicted from MC-I damage in the extrastriatal regions of the brain.
Insights
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes widespread mitochondrial complex I (MC-I) damage and reduces dopamine and serotonin transporter levels in a Parkinson
Area of Science:
- Neuroscience
- Radiochemistry
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder primarily affecting dopaminergic neurons.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model PD in non-human primates.
- The neurotoxic effects of MPTP on serotonergic systems and mitochondrial complex I (MC-I) are not fully understood.
Purpose of the Study:
- To compare the effects of MPTP on serotonergic neuronal systems and MC-I activity versus dopaminergic systems.
- To investigate the distribution and extent of MPTP-induced neurotoxicity in the brain using Positron Emission Tomography (PET).
Main Methods:
- A Parkinson disease monkey model was established through repeated MPTP administration.
- PET imaging was performed using radioligands targeting serotonin transporter (11C-DASB), serotonin 1A receptor (18F-MPPF), dopamine transporter (11C-PE2I), dopamine synthesis (11C-6MemTyr), dopamine D2 receptor (11C-raclopride), and MC-I (18F-BCPP-EF).
- Quantitative PET analyses were conducted using cerebellum as the input function for serotonin and dopamine parameters, and Logan plot analysis for MC-I.
Main Results:
- MPTP induced diffuse reductions in MC-I activity across the brain, excluding the cerebellum.
- Significant reductions in presynaptic dopamine transporter and dopamine synthesis were observed in the striatum and substantia nigra.
- MPTP reduced serotonin transporter binding in both striatal and extrastriatal regions, correlating with MC-I reduction in the cortex; serotonin 1A receptor binding remained unaffected.
Conclusions:
- Chronic MPTP treatment causes significant neurotoxicity extending beyond the nigrostriatal pathway, affecting both dopaminergic and serotonergic systems.
- MPTP-induced MC-I damage in extrastriatal regions supports its non-exclusive neurotoxicity to the nigrostriatal pathway.
- Multiparametric PET imaging reveals widespread neurochemical alterations in an MPTP-induced Parkinson's disease monkey model.
More Related Videos
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...